Senior Director of chemistry and CMC
Roger Léger, PhD serves as Senior Director of Chemistry and CMC at Thrasos Therapeutics. He oversees the chemistry efforts for the company from discovery to clinical trials. Prior to joining Thrasos, Dr Léger was Vice President of Research at Indel Therapetics Inc. a Vancouver BC based company working to discover and develop new antibiotics to treat drug resistant pathogenic bacteria. He was also co-founder and Vice President R&D Chemistry at Ulysses Pharmaceuticals Inc., a company with the objective of bringing improved products into clinical trials to cure difficult to treat bacterial infections. Dr Léger also served as Director of medicinal chemistry at ConjuChem Inc., a public company involved in the improvement of peptides and small molecules to treat obesity, diabetes, growth hormone deficiencies, hypertension, cancer and HIV/AIDS. He also served as Research Fellow at Microcide Pharmaceutics Inc., a public company engaged in the discovery and development of new antimicrobial agents effective against drug resistant pathogenic microorganisms.
Dr Léger is a co-inventor on 13 issued patents and numerous applications. He received a BSc and a PhD from the University of Montreal and he was an NSERC post-doctoral fellow at the University of Geneva and Columbia University in New York City.